ProShares UltraShort Nasdaq Biotechnology (BIS)

On our desk, looking at the recent Q2 2026 institutional filings for BIS, we see only 2 hedge funds and large institutions holding roughly $677K. The liquidity is exceptionally tight with a market cap sitting around $1.79M, making position sizing extremely sensitive to execution slippage.

From a risk management standpoint, short interest in BIS experienced a sharp contraction of 62.5% during late May down to 6,057 shares, representing about 4.3% of the stock. With a short-interest ratio of roughly 1.1 days based on sparse average daily volume, squeeze dynamics are virtually non-existent.

As a quant reviewing the V-Lab Zero Slope Spline-GARCH volatility analysis for BIS, the annualized volatility forecast is hovering near 43.81% for a 1-month horizon. With short-run deviations decaying at a half-life of 27 trading days, managing overnight holding risk on this inverse product requires rigorous mathematical oversight.

Tracking the pricing action through mid-2026, BIS has traded across a 52-week high of $33.13 and a low of $12.37, recently hovering around the $13.22 to $13.55 range. The expense ratio is fixed at 0.95%, which structurally penalizes long-term holders of inverse leveraged structures.

As a bio-analyst and tactical allocator, utilizing BIS requires strict intraday discipline rather than swing holding. ProShares manages the vehicle under a standard ETF structure with an inception date back in April 2006, but the microscopic capital inflows and minimal fund count indicate it remains a fringe instrument.